Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.

Real-time index price for TSX Industrials Capped Index (TTIN), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

S&P Global, a financial-data firm, expects sales of Lilly’s obesity drugs to overtake Novo’s by 2027 (see chart 1). PREMIUM Eli-Lilly-looks-set-to-steal-Novo-Nordisk-s-weight Investors are ...

Eli Lilly is proving that being second ... Its share price has fallen by a third since the start of 2024; Lilly’s has risen by about as much (see chart 1). Chart: The Economist The momentum ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.